Boston Scientific Expects Silk Road Medical Deal To Be Immaterial To Adjusted EPS In 2024 And 2025, And Accretive Thereafter
Portfolio Pulse from Benzinga Newsdesk
Boston Scientific expects its acquisition of Silk Road Medical to be immaterial to adjusted EPS in 2024 and 2025, but accretive thereafter. Silk Road Medical projects net revenue of $194-198 million in 2024, a 10-12% growth over the prior year. The transaction is expected to close in the second half of 2024.
June 18, 2024 | 11:04 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Boston Scientific's acquisition of Silk Road Medical is expected to be immaterial to adjusted EPS in 2024 and 2025, but accretive thereafter. The impact on GAAP EPS may be less accretive or dilutive due to amortization and acquisition-related charges.
The acquisition is not expected to significantly impact Boston Scientific's adjusted EPS in the short term (2024-2025), but will be accretive in the long term. The GAAP EPS impact may be less favorable due to amortization and acquisition-related charges.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Silk Road Medical projects net revenue of $194-198 million in 2024, representing a 10-12% growth over the prior year. The acquisition by Boston Scientific is expected to close in the second half of 2024.
Silk Road Medical's projected revenue growth and the upcoming acquisition by Boston Scientific are positive indicators for the company's short-term performance.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80